Current Status: Active PolicyStat ID: 9820295

Beaumont

Origination: 7/13/2021
Effective: 7/13/2021
Last Approved: 7/13/2021
Last Revised: 7/13/2021
Next Review: 7/13/2023
Document Contact: Kimberly Cole: Lab Quality

Coord

Area: Laboratory-Blood Bank

Key Words:

Applicability: Dearborn

Hemoglobin S Solubility Testing of Patients - Sickledex Method

Document Type: Procedure

I. PURPOSE AND OBJECTIVE:

The purpose of this document is to provide procedural steps that will be used to test patient samples for presence of hemoglobin S (Hb-S).

II. PRINCIPLE:

SICKLEDEX® is a qualitative solubility test for testing for the presence of sickling hemoglobins in human blood. SICKLEDEX® uses Saponin to lyse the test RBCs and release the hemoglobin. Sodium hydrosulfite then reduces the released hemoglobin. Reduced Hb-S is insoluble in the concentrated phosphate buffer solution and forms a turbid suspension that can be easily visualized. Normal hemoglobin A and other hemoglobins remain in solution under these conditions. These different qualitative outcomes allow for the visual detection of sickle cell disease and its traits.

III. SCOPE:

Patient samples are tested for Hb-S as described in this document for screening purposes only. It does not distinguish between sickle cell disease and sickle cell trait. Confirmatory hemoglobin evaluation testing performed in other laboratories is used to diagnose patients with sickle cell disease.

IV. POLICIES:

- A. Reagents, and controls must be within their expiration date when testing for Hb-S.
- B. Positive screening results must be verified by a second technologist before reporting and sent to special chemistry for a confirmatory hemoglobin electrophoresis.
- C. The Sickledex screening test is performed once per lifetime at this institution. All subsequent orders should be canceled per policy.

V. DEFINITIONS:

A. Cloudy, turbid suspension

- A suspension that is sufficiently opaque as to obscure the ruled lines on the test tube rack, so they
 are not visible when looking through the test tube.
- B. Transparent suspension
 - A suspension that is clear enough that the ruled lines on the test tube rack are visible when looking through the test tube.
- C. Hb-S
 - 1. Hemoglobin S

VI. SPECIMEN COLLECTION AND HANDLING:

- A. No patient preparation is required prior to specimen collection.
- B. The preferred specimen is a 4 ml K₂EDTA sample with affixed identifying label.
- Clotted samples must never be tested.
- D. Samples that have been refrigerated at 1°C to 10°C for up to 45 days may be tested.
- E. Specimens must be centrifuged for 5-10 minutes at 3500 RPM to obtain packed cells for testing.

VII. REAGENTS/STORAGE:

- A. SICKLEDEX[®] solubility buffer (a 2.3 M potassium phosphate buffer solution with 0.1% 2-chloroacetamide preservative). Store tightly capped at 2 °C 30 °C in the refrigerator. Do not used beyond the expiration date.
- B. SICKLEDEX[®] reagent powder vials (contain Saponin and sodium hydrosulfite). Store tightly capped at 2
 °C 30 °C in the refrigerator. Do not use beyond the expiration date.

Warning: Sodium Hydrosulfite is a flammable solid and a strong reducing agent. Keep container tightly closed and dry. Avoid contact with eyes and skin. Refer to SDS.

- C. The reconstituted SICKLEDEX® solubility buffer is prepared by reconstituting the SICKLEDEX® reagent powder in the SICKLEDEX® solubility buffer, as described in the Procedure of this document.
 - 1. Expires 45 days after the date of preparation, not to exceed the original expiration of the buffer or reagent powder.
 - 2. Stored tightly capped at 2 °C 10 °C in the refrigerator. DO NOT FREEZE.
 - Allowing the entire bottle of the reconstituted buffer to warm to room temperature may reduce the open-bottle stability.
 - 4. A slight sediment may form during storage.
- D. Sickle-Chex® controls (Hb-S positive and negative controls, stabilized human RBCs in a preservative medium, manufactured by Streck). Expires 100 days after opening, not to exceed the original expiration date. Stored tightly capped at 2 °C 10 °C in the refrigerator.

VIII. EQUIPMENT:

A. Plastic test tube holder, with 2 mL line marking and additional black lines which are used to assess the test solution in the test tubes for turbidity

B. Pipette capable of dispensing 10 µL packed RBCs.

IX. SUPPLIES:

- A. Dispenser caps (for the working SICKLEDEX® solubility buffer)
- B. Disposable 12 x 75 mm test tubes, glass or plastic
- C. Disposable pipette tips

X. QUALITY CONTROLS (QC):

- A. Positive and negative commercial controls are tested with each batch of testing to check for proper test procedure and reagent reactivity and to compare unknown specimen test results with control test results to assure proper reporting.
- B. As an alternative known positive (AS) and negative (AA) patient controls may be obtained from special testing along with patient hemoglobin electrophoresis reports.
- C. Inability to obtain the expected results for the positive and negative controls may indicate deterioration of the controls.
- D. Moderate darkening of the supernatant of the controls is normal; however darkly colored supernatant may be indicative of product deterioration.
- E. The Sickle-Chex® controls must be labeled with the date opened, the expiration date, and the technologist's initials.
- F. The reconstituted buffer must be labeled with the reconstitution date, the new expiration date, and the technologist's initials
- G. Hb-S controls are documented in Softbank as described in the attachment Resulting QC Racks

XI. BEFORE YOU GET STARTED:

- A. Verify that reagents and controls are within their expiration date.
- B. Allow the controls and patient samples to warm to room temperature (18°C 30 °C), approximately 15 minutes.
- C. Determine whether a sufficient volume of in-date, reconstituted buffer is available. If not, prepare as described below in Preparation of the Reconstituted SICKLEDEX® Solubility Buffer. **DO NOT remove the bottle of reconstituted buffer from refrigeration until immediately before testing.** Allowing the entire bottle to warm to room temperature may reduce the open-bottle stability.

XII. PROCEDURE: PREPARATION OF THE RECONSTITUTED SICKLEDEX® SOLUBILITY BUFFER

- A. Determine whether a sufficient volume of in-date, reconstituted buffer is available. If not, prepare as described in the following steps.
 - 1. Allow 1 bottle of SICKLEDEX® solubility buffer and 1 vial of SICKLEDEX® reagent powder to warm to room temperature (18°C 30 °C).

- 2. Add the contents of the SICKLEDEX® reagent powder vial to the bottle of SICKLEDEX® solubility buffer.
- 3. Place a dispenser cap on the bottle. Dissolve the reagent powder completely with vigorous agitation.
- Record the reconstitution date in the space provided on the bottle of reconstituted buffer. Also record
 the new expiration date and technologist's initials. The reconstituted buffer may now be used for
 testing.
 - a. Expires 45 days after the date of preparation, not to exceed the original expiration of the buffer or reagent powder. When not in use, store tightly capped at 2 °C - 10 °C. A slight sediment may form during storage; this will not interfere with test results.

XIII. PROCEDURE: TESTING FOR HEMOGLOBIN S

- A. Follow the steps below to test patients and controls for Hemoglobin S.
 - 1. Remove the positive and negative controls from the refrigerator. Allow them to warm to room temperature (18°C 30 °C) for 15 minutes before use.
 - 2. Centrifuge all patient samples for 5-10 minutes at 3500 RPM to obtain proper cell separation.
 - 3. Label a 12 x 75 mm test tube with the patient identifier for each sample to be tested. Also label a tube for the positive control and another for the negative control.
 - 4. Place each test tube in the plastic test tube holder (has a 2 mL line marking and additional lines which are used to assess the test solution in the test tubes for turbidity).
 - 5. Dispense 2 mL of cold reconstituted buffer to each labeled tube (to the 2 mL line) and allow the contents of the tubes to warm to room temperature (18°C 30 °C) for at least 10 minutes.
 - a. The use of reconstituted buffer solution below room temperature may give false results.
 - b. DO NOT remove the bottle of reconstituted buffer from refrigeration until immediately before testing. Allowing the entire bottle to warm to room temperature may reduce the open-bottle stability.
 - 6. Pipet 10 µL packed RBCs from the bottom tube and it to the correspondingly labeled test tube.
 - 7. Ensure the positive and negative controls have had time to warm to room temperature (18°C 30 °C) for at least 15 minutes before use. Mix the contents of the positive and negative controls as follows. Do not mix mechanically.
 - a. Hold vial vertically between the palms of the hands and roll the vial back and forth for 20 to 30 seconds.
 - Mix by rapid inversion to ensure the cells are suspended. Vials stored for an extended period of time may require extra mixing.
 - c. Gently invert the vials 8 to 10 times before sampling.
 - d. The Sickle-Chex® controls must be labeled with the date opened, the expiration date, and the technologist's initials.
 - Transfer 20 μL (1 drop) of the well-mixed positive and negative controls to the correspondingly labeled test tubes. To ensure the correct delivery volume of controls, the vials must be inverted and held vertically directly over the test tube.



Correct Delivery Angle




Incorrect Delivery Angle

- Mix the contents of all tubes thoroughly by swirling each tube several times. Return each test tube to the test tube holder.
- 10. Return all reagents and controls to the refrigerator. For the positive and negative controls, wipe the threads of the vials and caps before returning to refrigeration.
- 11. Allow the tubes to stand at room temperature (18°C 30 °C) for at least 6 minutes.
 - a. Positive results will occur 6 minutes after the addition of the RBCs to the working buffer solution.
 - b. Results may be observed for up to 60 minutes.
 - c. Negative donor results may not clear as quickly or completely as the negative control.
- Read and interpret the reactions. A reaction is read macroscopically by looking through the solution in the tube at the black lines of the test tube rack. Refer to the Interpretation section of this document.
- 13. If patient result is positive,
 - a. Testing should be repeated using washed cells before reporting
 - i. Wash patient specimen once with saline and centrifuge.
 - ii. Decant the supernatant
 - iii. Repeat test with the washed packed cells.
 - b. Show both original and repeat tests to a second technologist for confirmation before reporting positive result
 - c. Hemoglobin Evaluation is automatically ordered by LIS on all positive screening results. Send specimen to Special Chemistry for confirmatory Hemoglobin Electrophoresis testing.
- 14. Document the results of the quality control in the Blood Bank computer system as described in attachment *Resulting the QC Rack*.
- 15. Document Hb-S results for the patients are documented in Beaker LIS as described in the attachment *Resulting Patient Sickle Cell Screen Results*.

XIV. INTERPRETATION:

A. Interpret the Hb-S test as positive or negative, as described below. Hb-S results for the patients are documented in Beaker as described in the attachment *Resulting Patient Sickle Cell Screen results*.



B. Expected Results

Normal = Negative

The estimated frequency of Hgb S/S in the U.S. population is one in four thousand (0.025%) and one in one hundred (1%) for the heterozygous genotype. The homozygous form of Sickle Cell Disease affects 0.3% of the black population. The heterozygous form of the disease (Sickle Cell Trait) affects more than 8% of the black population.

XV. LIMITATIONS:

- A. False negative results may occur in patients if
 - The working buffer is not allowed to come to room temperature before testing
 - 2. Hb S concentration is below the sensitivity of Sickledex
 - a. Testing patients younger than 6 months of age (due to the presence of Hgb F)
 - Patient had transfusion which decreases Hgb S below 30%
 - 3. 10 x 75 test tubes are used in error
- B. False positive results may occur in patient if:
 - 1. Samples have abnormal proteins, or elevated levels of protein
 - 2. Samples have hyperlipidemia
 - Patient had transfusion with HbS positive blood
 - 4. Patients suffers from extremely high hemoglobin, erythrocytosis, or leukocytosis
 - 5. Patients have rare sickling hemoglobin subtypes such as Hb-C Harlem, Hb-C Georgetown, Hb-C Ziguinchor and Hb-S Travis.

XVI. REFERENCES:

- 1. SICKLE-Chex® Instructions for Use, Streck, 350413-13, 2017-12.
- 2. SICKLEDEX® Instructions for Use, Streck, 350430-21, 2017-12.

Attachments



b64_2f61f4b1-6543-4d54-9d0a-e968cd1a04d6

Resulting the Manual QC Racks.pdf

Resulting Patient Sickle Cell Screening Tests.pdf

Approval Signatures

	Step Description	Approver	Date
		Jeremy Powers: Chief, Pathology	7/13/2021
	Policy and Forms Steering Committe (if needed)	Kimberly Cole: Lab Quality Coord	7/7/2021
	Policy and Forms Steering Committe (if needed)	Gail Juleff: Project Mgr Policy	7/7/2021
		Kelly Sartor: Supv, Laboratory	7/7/2021
		Kimberly Geck: Dir, Lab Operations B	7/6/2021
		Kimberly Cole: Lab Quality Coord	7/6/2021


Applicability

Dearborn

Resulting Patient Sickle Cell Screen Tests

Beaumont

Beaumont Laboratory
Dearborn



Printed copies of this document are not considered up-to-date. Please verify current version date with online document, 04/08/2021

Beaumon

Beaumont Laboratory, Dearborn

Reagent Checks**


- Expiration Dates: Evaluate the reagent in each rack for expiration dates. Discard and replace with a new lot any reagent expiring on the current date.
- Appearance: Evaluate the appearance of each reagent in the rack. All reagents should be free from turbidity. Red cell supernatants should be clear/ colorless and free from marked hemolysis.
- Additional Reagent Lots: Add reagent data in the first available line at the bottom of grid. Click/Hit F5-Reagents on enter the reagent and lot# information. Add control type (QCPOS or QCNEG) in the Test field. Perform QC as usual.

Resulting Manual QC Racks

For use with QCT,

QCG, DQDAT &

DOLIS Racks



If the rack has already been completed on the current date (e.g., you are adding a new lot # to the rack, adding special antisera QC, sickle cell or fetal screen controls) . . .

- Place cursor on the next available line in the QC Tests Results window.
- Click F5 -Reagents.
- Document the Reagents and Controls fields.
- Verify that the reagent TEST field is documented correctly (as QCPOS, QCNEG, or QCDOC).